戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 or CV1-FHC, 2.9 +/- 0.3 x 10(-3) for CV1-FHC-ferric citrate).
2 moglobin levels were statistically higher on ferric citrate.
3 C (ferric citrate-binding protein C)], binds ferric citrate.
4 ast Saccharomyces cerevisiae were grown with ferric citrate.
5 al transitions in response to the binding of ferric citrate.
6 ed in MCF-7 cells cultured with supplemental ferric citrate.
7 ited equivalent rates of uptake of 55Fe from ferric citrate.
8 f serious adverse events were similar in the ferric citrate (12.0%) and placebo groups (11.2%).
9 travenous elemental iron (median=12.95 mg/wk ferric citrate; 26.88 mg/wk active control; P<0.001) and
10 tin-equivalent units per week: 5306 units/wk ferric citrate; 6951 units/wk active control; P=0.04).
11          Thus, our data suggest that enteral ferric citrate absorption is dependent on conventional e
12       Next, to assess whether or not enteral ferric citrate absorption is dependent on ferroportin, w
13                                  Subjects on ferric citrate achieved higher mean iron parameters (fer
14    Significantly more patients randomized to ferric citrate achieved the primary end point (61 [52.1%
15 echanisms by which they may act, and whether ferric citrate affects chronic kidney disease progressio
16                               Interestingly, ferric citrate also lessened systemic inflammation, impr
17 ontrol period phosphorus was similar between ferric citrate and active control, with comparable safet
18 e clusters that likely serve in transport of ferric citrate and ferrioxamine.
19 mpared the mean change in phosphorus between ferric citrate and placebo during the placebo control pe
20 (18.8%) and 15 (12.9%) patients treated with ferric citrate and placebo, respectively.
21 reus ATCC 14579 takes up (55)Fe radiolabeled ferric citrate and that a protein, BC_3466 [renamed FctC
22  suppressor mutant, respiration of fumarate, ferric citrate, and DMSO was restored but that of nitrat
23 t labile, and could utilize ferric chloride, ferric citrate, and human holotransferrin as substrates.
24  it binds and transports iron in the form of ferric citrate, and second, it initiates a signaling cas
25                                   We studied ferric citrate as a phosphorus binder and iron source.
26  with hemoglobin, transferrin, ferritin, and ferric citrate as iron sources.
27 e wild-type parent strain when supplied with ferric citrate as the iron source.
28  FecA from Escherichia coli with and without ferric citrate at 2.5 and 2.0 angstrom resolution.
29 es transcriptional activation in response to ferric citrate binding at the cell surface.
30 ferric citrate import system is regulated by ferric citrate binding to the outer membrane transporter
31 e and that a protein, BC_3466 [renamed FctC (ferric citrate-binding protein C)], binds ferric citrate
32 n characterized; little is known about other ferric citrate-binding proteins.
33 -dichlorophenolindophenol, several quinones, ferric citrate, bovine cytochrome c, and O(2) accepted e
34 fashion and c-myc expression was enhanced by ferric citrate compared to sodium citrate control.
35 sting that iron moves through the xylem as a ferric-citrate complex.
36 ctrometry (nano ESI-MS) analysis of FctC and ferric citrate complexes or citrate alone show that FctC
37 rium Bacillus cereus that binds multinuclear ferric citrate complexes.
38                                              Ferric citrate controlled phosphorus compared with place
39 per 1.73 m(2) 2:1 to receive a fixed dose of ferric citrate coordination complex (two tablets per mea
40            To investigate whether fixed-dose ferric citrate coordination complex favorably affects mu
41 and hospitalization, suggest that fixed-dose ferric citrate coordination complex has an excellent saf
42         The beneficial effects of fixed-dose ferric citrate coordination complex on biochemical param
43                                              Ferric citrate coordination complex significantly increa
44                    Compared with usual care, ferric citrate coordination complex treatment resulted i
45            Of the 133 patients randomized to ferric citrate coordination complex, 31 (23%) initiated
46                                              Ferric citrate-delivered iron is enterally absorbed, but
47 that were most responsive to the presence of ferric citrate did not follow a trend similar to that of
48 e nephropathy model, where three weeks of 1% ferric citrate dietary supplementation again failed to i
49 erroportin-deficient mice, three weeks of 1% ferric citrate dietary supplementation, a dose that prev
50 we evaluated the effects of five weeks of 1% ferric citrate dietary supplementation.
51                                              Ferric citrate (FC) is a phosphate binder with shown eff
52  uptake systems for elemental iron (efeUOB), ferric citrate (fecCDEF), and petrobactin (fpbNOPQ) are
53 t be reversed by the addition of iron salts, ferric citrate, ferric nitrate, or ferric transferrin.
54  and TBI uptake, we injected (59) Fe-labeled ferric citrate (for NTBI) or (59) Fe-transferrin into pl
55 bsorption and possibly improved iron status, ferric citrate greatly reduced circulating fibroblast gr
56 r the control group versus 84.7 mg/d for the ferric citrate group (P < 0.005).
57 ints reached statistical significance in the ferric citrate group, including the mean relative change
58                   In chronic kidney disease, ferric citrate has been shown to be an effective phospha
59                                              Ferric citrate hydrate (FC) is an iron-based phosphate b
60                         Transcription of the ferric citrate import system is regulated by ferric citr
61 transcriptional activation is not coupled to ferric citrate import, an allosteric mechanism underlies
62  on ferroportin, we evaluated the effects of ferric citrate in a tamoxifen-inducible, enterocyte-spec
63   Here, we first demonstrate the efficacy of ferric citrate in high hepcidin models, including Tmprss
64 brosis, suggesting renoprotective effects of ferric citrate in the setting of chronic kidney disease.
65                                        Thus, ferric citrate is an efficacious and safe phosphate bind
66                                              Ferric citrate is approved as an iron replacement produc
67                                 As expected, ferric citrate lowered serum phosphate concentrations an
68 , and O(2), as well as the ability to reduce ferric citrate, manganese(IV), nitrate, and nitrite.
69 ation constant (K(d)) of FctC at pH 7.4 with ferric citrate (molar ratio 1:50) is 2.6 nM.
70 a to compare the safety and efficacy of oral ferric citrate (n=117) and placebo (n=115).
71 ide (TMAO), thiosulfate, dimethyl sulfoxide, ferric citrate, nitrate, and O(2), as well as the abilit
72 rce of enteral iron; however, the effects of ferric citrate on the kidney have been less well-studied
73  441 subjects on dialysis were randomized to ferric citrate or active control in a 52-week active con
74 e active control period were rerandomized to ferric citrate or placebo.
75                    Only the Escherichia coli ferric citrate outer-membrane transport protein FecA has
76                                  Subjects on ferric citrate received less intravenous elemental iron
77               The factors mediating possible ferric citrate renoprotection, the mechanisms by which t
78 r, inhibited Zip14-mediated iron uptake from ferric citrate, suggesting that iron is taken up by HEK
79 all, in patients with NDD-CKD, we found oral ferric citrate to be a safe and efficacious treatment fo
80                 Many bacteria and plants use ferric citrate to fulfill their nutritional requirement
81 lis strains were found to be able to utilize ferric citrate, transferrin, lactoferrin, and heme as so
82 transporter initiate two independent events: ferric citrate transport into the periplasm and transcri
83 sized and transported enterobactin and had a ferric citrate transport system but lacked the ability t
84 t transporters, such as the Escherichia coli ferric citrate transporter FecA, interact with the inner
85 cribe three structures of the outer membrane ferric citrate transporter FecA: unliganded and complexe
86 plasmic ferric transport protein, a putative ferric citrate transporter, and ferritin, respectively.
87                                       In the ferric citrate transporter, FecA, SDSL indicates that th
88 , the vitamin B12 transporter, and FecA, the ferric citrate transporter.
89 treated group (P = 0.058), 77.0 mg/d for the ferric citrate-treated group (P = 0.057), and 62.5 mg/d
90                                   Binding of ferric citrate triggers a conformational change of the e
91 d to encode homologs of the Escherichia coli ferric citrate uptake regulators FecI and FecR.
92 otable genes were identified associated with ferric citrate uptake, lactose fermentation and resistan
93                                 Reduction of ferric citrate was accompanied by oxidation of the cytoc
94 upplemented with hemoglobin, whole blood, or ferric citrate was not affected, suggesting additional s
95 placebo control period, in which subjects on ferric citrate who completed the active control period w